Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Argenx Se (ARGX)
Argenx Wins FDA Nod Expanding VYVGART Label To All Adult GMG Patients
5/11/2026 5:29:42 AM
Argenx Q1 Revenue Jumps; Key Milestones Ahead For VYVGART Expansion And Empasiprubart; Stock Up
5/7/2026 5:13:22 AM
Argenx SE Q1 Income Rises
5/7/2026 1:16:57 AM
Argenx Posts Q1 Global Product Net Sales Of $1.3 Bln, Up 63% Year-over-year
5/7/2026 1:10:37 AM
Argenx Q1 EPS Climbs To $5.52 From $2.58 Last Year
5/7/2026 1:10:09 AM
Biotech Stocks Facing FDA Decision In May 2026
4/28/2026 8:01:15 AM
Wedbush Analyst Reiterates Argenx SE At Outperform With $1000 Price Target
4/23/2026 11:15:17 AM
Biotech Stocks Facing FDA Decision In May 2026
4/23/2026 7:33:01 AM
AAN 2026: Neurology Pipeline Advances Spotlight Myasthenia, Epilepsy, MS And Parkinson's Progress
4/17/2026 10:49:08 AM
Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX
2/27/2026 9:17:16 AM
Argenx Posts Strong 2025 Results And Reports Positive Phase 3 Results In Ocular MG
2/26/2026 7:39:21 AM
Argenx Announces Positive Phase 3 ADAPT OCULUS Study Of VYVGART In Adults With Ocular Myasthenia Gravis
2/26/2026 4:26:51 AM
Argenx Phase 3 ADAPT OCULUS Study Of Vyvgart Meets Primary Goal In Ocular Myasthenia Gravis
2/26/2026 3:24:18 AM
Argenx SE Bottom Line Falls In Q4
2/26/2026 1:51:31 AM
Argenx Phase 3 ADAPT OCULUS Trial Of VYVGART Meets Primary Endpoint In Ocular Myasthenia Gravis
2/26/2026 1:36:24 AM
Argenx FY EPS $8.02, Down From $11.79 Last Year
2/26/2026 1:17:48 AM
Older Articles